about
Does fat suppression via chemically selective saturation affect R2*-MRI for transfusional iron overload assessment? A clinical evaluation at 1.5T and 3T.Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.Iron overload in sickle cell disease.Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.Magnetic resonance imaging measurement of iron overload.The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload.Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition.Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.Simultaneous field and R2 mapping to quantify liver iron content using autoregressive moving average modeling.Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicityReal-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.Automated T(2) * measurements using supplementary field mapping to assess cardiac iron content.Regulation of iron absorption in hemoglobinopathies.Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease.Trends in transfusion burden among long-term survivors of childhood hematological malignancies.Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.Iron overload: consequences, assessment, and monitoring.Iron in sickle-cell disease: what have we learned over the years?Chelation treatment in sickle-cell-anaemia: much ado about nothing?Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overloadUtility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence.Can multi-slice or navigator-gated R2* MRI replace single-slice breath-hold acquisition for hepatic iron quantification?Liver injury is associated with mortality in sickle cell disease.Cardiac abnormalities in children with sickle cell anemia.The impact of preparation and support procedures for children with sickle cell disease undergoing MRI.Automated vessel exclusion technique for quantitative assessment of hepatic iron overload by R2*-MRI.Radial Ultrashort TE Imaging Removes the Need for Breath-Holding in Hepatic Iron Overload Quantification by R2* MRI.Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects.Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.Quantitative ultrashort echo time imaging for assessment of massive iron overload at 1.5 and 3 Tesla.
P2860
Q30989859-30F3685E-135F-462E-9D85-395FD316A909Q33411923-A86A9E12-0FD0-4A73-B0F6-6555F82B62F6Q33420358-8F981804-B31E-43F0-949F-C400C2E8B183Q33861129-3E4A70F1-1BD4-4FA6-8A2F-476C0215BFCFQ33909056-45F100A3-6899-4DED-92AE-146580D90E37Q33944366-49A7032D-10AB-43F5-8C77-AD5F0B25D0C6Q34181082-8B2348FF-B378-478E-8B4C-D1E382535833Q34339812-9705F429-0682-47D5-900D-B31D2646722FQ34786236-B03F2130-01AA-4124-AF31-4F2CC0A6BC22Q35206809-E5E1D955-7EFC-48EE-B254-7A8046727F0FQ35848307-F21BDEA3-83CD-4B3F-9986-7223339D5FE0Q35896606-04340BBF-33E7-4DD3-B23B-3AD378A8814AQ35906193-251F18B2-982B-4852-A9FA-BF1733A9D6D7Q36524624-02054F32-4F5E-44D3-9141-EBB83EE0C3D6Q36642048-45DA7ED2-F6E3-4963-9B52-49AA66A72B64Q37064261-5EDC14AA-7ABE-43C6-9A7A-62AE842FEE59Q37320318-4DF30244-8947-4031-A6B5-344A9ECD3A96Q37398351-2C26361E-26AE-4906-A4EA-9A5248D06DC4Q37590225-B1AA2DFF-FA6F-4CFB-BF96-2B3F3BAD6FE6Q37650448-16BA86C9-5526-4A92-9CAB-E3FD81BCD272Q37650453-0A7C34CD-AEE5-48A0-8E45-43067A40CF20Q37820936-D495283F-BB86-44AE-BBFD-C4ADFBC97C64Q37894822-7BDE6CAA-6008-4559-B962-C7A6E5608A06Q38280401-AE345695-A25E-4217-B02F-7C98692BA9D0Q38416115-39FE6146-B553-4325-806E-B4EED7A3E317Q38813089-6A072E06-6443-405F-A468-8E3AB6170368Q39279314-530D9BD5-6265-495A-B298-FBA3F0876C64Q41076119-40FE4DAC-B387-4E61-AB57-FA17228A934EQ45954970-F02BE900-D796-47F0-AF48-5A813E71E98EQ46072007-912EAD00-480D-4DA4-BB38-48CBAFE98061Q47399134-3D78F8C5-BC24-415D-AAE2-178F5DB03C92Q47891577-51674704-66D9-470E-80E4-FCF1058C2551Q50218898-ECFE21DF-B471-4F91-839F-4D70307F33CEQ50231452-AC932E49-A69A-4D29-8661-2BB5BD800B05Q50951880-C0863865-EA47-4228-98C4-854DEB418AE7
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Progression of iron overload in sickle cell disease.
@ast
Progression of iron overload in sickle cell disease.
@en
type
label
Progression of iron overload in sickle cell disease.
@ast
Progression of iron overload in sickle cell disease.
@en
prefLabel
Progression of iron overload in sickle cell disease.
@ast
Progression of iron overload in sickle cell disease.
@en
P1476
Progression of iron overload in sickle cell disease.
@en
P2093
Olivieri NF
P356
10.1016/S0037-1963(01)90060-5
P433
P577
2001-01-01T00:00:00Z